Gene-Silencing shot aims to quiet hepatitis b for good
NCT ID NCT07200193
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new therapy called CRMA-1001, which uses epigenetic gene silencing to turn off the hepatitis B virus in the body. About 66 adults with chronic hepatitis B who are already on antiviral pills will receive one or more IV infusions of the therapy. The main goal is to check safety and tolerability, while also looking at how the body processes the drug and whether it can reduce virus levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CRMA-1001 (epigenetic gene silencing therapy given by IV infusion)
What this could lead to
If successful, this could lead to a new way to control chronic hepatitis B by silencing the virus's genes, potentially reducing or eliminating the need for lifelong daily antiviral pills.
What could go wrong
This is an early phase 1/2 trial with only 66 participants, so safety and effectiveness are not yet proven. The therapy is new and may cause side effects or fail to control the virus long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospices Civils De Leon
RECRUITINGLyon, 69002, France
Contact
-
King's College Hospital
RECRUITINGLondon, SE5 9RS, United Kingdom
Contact
-
New Zealand Clinical Research
RECRUITINGAuckland, New Zealand
Contact
-
Queen Mary Hospital, The University of Hong Kong
RECRUITINGHong Kong, 999077, Hong Kong
Contact